Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2

KRAS mutation status can distinguish between metastatic colorectal carcinoma (mCRC) patients who may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab. However, patients whose tumors harbor mutant KRAS (codons 12/13, 61 and 146) are often excluded from...

Descripción completa

Detalles Bibliográficos
Autores principales: Brijwani, Nilesh, Jain, Misti, Dhandapani, Muthu, Zahed, Farrah, Mukhopadhyay, Pragnashree, Biswas, Manjusha, Khatri, Deepak, Radhakrishna, Vinod D., Majumder, Biswanath, Radhakrishnan, Padhma, Thiyagarajan, Saravanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431418/
https://www.ncbi.nlm.nih.gov/pubmed/28473715
http://dx.doi.org/10.1038/s41598-017-01566-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431418/
https://www.ncbi.nlm.nih.gov/pubmed/28473715
http://dx.doi.org/10.1038/s41598-017-01566-x

Ejemplares similares